RAPT Therapeutics (RAPT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RAPT Therapeutics, Inc. has encountered a setback as the FDA imposed a clinical hold on their Phase 2b and Phase 2a trials for zelnecirnon, due to a severe liver failure incident in a patient, which might be linked to the drug. The company has ceased dosing and new participant enrollment in the trials for atopic dermatitis and asthma, while their separate oncology trial for a different drug remains unaffected.
For further insights into RAPT stock, check out TipRanks’ Stock Analysis page.